Prognostic significance of peripheral blood flow cytometry parameters in patients with non-metastatic breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7645-7649

  Engin, Huseyin ^a   Bilir, Cemil ^a   Tekin, Ishak Ozel ^b  

^a ZKU Arastrima Ve Uygulama H   (Turkey)

^b ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Cytotoxic T cells; Flow cytometry parameters

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER GRADING; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LYMPH NODE; LYMPHOCYTE SUBPOPULATION; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; LYMPHOCYTE SUBSETS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84893425062     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7645     Document Type: Article

References (28)

1. Alkhateeb AA, Han B, Connor JR (2013). Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res Treat, 137, 733-44.
2. Berry DA, Cronin KA, Plevritis SK, et al (2005). Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med, 353, 1784-92.
3. Blake-Mortimer JS, Sephton SE, Carlson RW, Stites D, Spiegel D (2004). Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J, 10, 195-9.
4. Cho Y, Miyamoto M, Kato K, et al (2003). CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res, 63, 1555-9.
5. Curigliano G, Spitaleri G, Dettori M, et al (2007). Vaccine immunotherapy in breast cancer treatment: Promising, but still early. Expert Rev Anticancer Ther, 7, 1225-41.
6. Domschke C, Schuetz F, Ge Y, et al (2009) Intratumoral cytokines and tumor cell biology determine spontaneous breast cancerspecific immune responses and their correlation to prognosis. Cancer Res, 69, 8420-28.
7. Effros RB (2004). Replicative senescence of CD8+ T cells: potential effects on cancer immune surveillance and immunotherapy. Cancer Immunol Immunother, 53, 925-33.
8. Emens LA, Reilly RT, Jaffee EM (2004). Augmenting the potency of breast cancer vaccines: Combined modality immunotherapy. Breast Dis, 20, 13-24.
9. Fehervari Z, Sakaguchi S (2004). CD4+ Tregs and immune control. J Clin Invest, 114, 1209-17.
10. Gökmen NM, Gökmen E (2011). Analysis of lymphocyte subtypes by flow cytometry after adjuvant chemotherapy for early-stage breast cancer. Ege J Med, 50, 33-8.
11. Hinkel A, Tso CL, Gitlitz BJ, et al (2000). Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. J Immunother, 23, 83-93.
12. Kagi D, Ledermann B, Burki K (1994). Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature, 369, 31-7.
13. Kagi D, Ledermann B, Burki K (1996). Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol, 14, 207-32.
14. Leong PP, Mohammad R, Ibrahim N, et al (2006). Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett, 102, 229-36.
15. Liang J, Wang C, Chang K (1993). Circulating intercellular adhesion molecule-1 and lymphocyte subsets involved in immune response of breast cancer. Sheng Wu Chi Mien Hsuen Tsa Chih, 26, 1-5.
16. Matsuura K, Yamaguchi Y, Ueno H, et al (2006). Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer, 106, 1227-36.
17. Melichar B, Touskova M, Dvorak J, et al (2001). Peripheral blood leukocyte phenotype in patients with breast cancer: Effect of doxorubicin/paclitaxel combination chemotherapy. Immunopharmacol Immunotoxicol, 23, 163-73.
18. Rakha EA, El-Sayed ME, Lee AH, et al (2008). Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol, 26, 3153-58.
19. Rey-Ferro M, Castaño R, Orozco O, Serna A, Moreno A (1997). Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition, 13, 878-81.
20. Scheuring UJ, Sabzevari H, Theofilopoulos AN (2002). Proliferative arrest and cell cycle regulation in CD8+CD28-versus CD8+CD28+ T cells. Hum Immunol, 63, 1000-9.
21. Schmidt M, Böhm D, von Törne C, et al (2008). The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res, 68, 5405-13.
22. Schwartz GF, Hughes KS, Lynch HT, et al (2008). Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management. Cancer, 113, 2627-37.
23. Shen Y, Qu QX, Zhu YB, et al (2012). Analysis of Cd8+Cd28-T-suppressor cells in gastric cancer patients. J Immunoassay and Immunochem, 33, 149-55.
24. Shu S, Plautz G, Krauss J (1997). Tumor immunology. JAMA, 278, 1972-81.
25. Siegel R, Ward E, Brawley O, et al (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212.
26. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR (2005). Molecular evolution of breast cancer. J Pathol, 205, 248-54.
27. Van der Hage JA, Mieog JS, van de Velde CJ, et al (2011). Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials. Breast Cancer Res, 13, 68.
28. Wang YX, Ruan CP, Li L, Shi JH, Kong XT (1999). Clinical significance of changes of perioperative T cell and expression of its activatedantigen in colorectal cancer patients. World J Gastroenterol, 5, 181-2.